Physicians' Academy for Cardiovascular Education

Need for ongoing clinical innovation in management of T2DM: A closer look at the development process of new entities

July 30, 2016 - Asian Interchange on Diabetes meeting - Michael Mark, MD, Boehringer Ingelheim – Cardiometabolic Diseases Research

Michael Mark illustrates the full trajectory of development of the SGLT2 inhibitor empagliflozin, from finding a therapeutic target through testing clinical effects of the newly developed therapeutic agent.

This lecture was recorded at the Asian Interchange on Diabetes meeting, held in Bangkok on July 30-31, 2016.

Video navigation menu

  • Why do we need ongoing clinical innovation for the management of T2DM? 0:21
  • The drug discovery and development process is a long and challenging trajectory 3:43
  • Discovery of the SGLT2 transporter as a therapeutic target and finding an inhibitor 6:50
  • Testing the identified compound and developing a drug 13:34
  • Results of the phase I, II and III trials evaluating a SGLT2 inhibitor 16:35
  • Meeting unmet needs in diabetes care: is that enough? 20:07